Neal Akhave

Asst. Professor of Thoracic/Head and Neck Medical Oncology at @MDAndersonNews, specializing in cancers of the oral cavity. Views are my own. #EndCancer

[Head and Neck Cancer Alliance @hncalliance]

Medical and dental clinics can host head and neck cancer screenings year-round. We provide the materials you need to educate your community, promote your event, and support volunteers. You focus on staffing and logistics. We’ll send the tools.
https://t.co/mv1qUAP1lb

[Lauren Averett Byers, MD @LaurenByersMD]

Congratulations to our Thoracic/HN Medical Oncology teams for a great research retreat. Excited for all of the great science and what is yet to come. #EndCancer #LCSM #HNCSM @MDAndersonNews

[Neal Akhave @NealAkhave]

@esinghimd @cancerGRACE @JackWestMD @jillfeldman4 @melinda_bachini @GoldmanLisa @AnaVManana @guptaarjun90 @fischmd @thenasheffect @NarjustFlorezMD Really great work! Can really see myself using this with my patients!

[Eric K. Singhi, MD @lungoncdoc]

1/ The first medical #oncology visit for a patient with a new #cancer diagnosis can be overwhelming to navigate.

I’ve worked with @cancerGRACE & patient advocates to create a ☝🏽page (✌🏽sided) patient guide to the initial medical oncology visit, offered both in English & Spanish.

[Luana Sousa, MD @LuanaGSousaMD]

📌Check out our most updated review in ACC #adenoidcysticcarcinoma #rarecancers https://t.co/cTD7VveARo

[Total Health™ @TotalHealthConf]

Phase 1 first-in-human trial of first in class agent 👉🏼PC14586, TP53 activator in cancers with Y220C mutation ! Wow responses in P53 mutations
✅ORR 32% at active dose @ASCO #ASCO22

[Vivek Subbiah, MD @VivekSubbiah]

🚨Hot off the press @NEJM 👉PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer👉All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response !!! @ASCO #ASCO22 @OncoAlert #PrecisionMedicine https://t.co/dpneZ3VpD7

[Mirella Nardo, MD @mirella_nardo]

Yeah, this is my boss, people! 😎#ASCO22 #PrecisionMedicine @MDAndersonNews

[Neal Akhave @NealAkhave]

@NitinJainMD @Ash @ASCO @doctorpemm @mpdrc @VivekSubbiah @Dr_AmerZeidan @BldCancerDoc @szusmani @Transplant_Doc @LoriMuffly @Anand_88_Patel @MediHumdani This is an excellent thread! As difficult as it is, the ability to start with an idea and take it to the end is incredibly inspiring! Hope to be like you someday

[Neal Akhave @NealAkhave]

@hjcherng @BloodJournal @GreenLymphoLab @Lymphoma_Doc @MDAndersonNews Congrats Jeff!!

[Eric K. Singhi, MD @lungoncdoc]

Such a surreal feeling to reflect on my hematology/oncology fellowship experience thus far during my PGY-6 talk last week. Here are some of the key “take-aways” that I’ve learned during my time in training, a 🧵:

[Vivek Subbiah, MD @VivekSubbiah]

🚨First data for sotorasib in patients w pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy & safety @ASCO #ASCO22 plenaries @OncoAlert
➡️38 patients, 8 pts PR
✅ORR= 21.1% (95% CI: 9.55%-37.32%).
✅DCR= 84.2% @PanCAN

https://t.co/r5wKgEOTSI

[Vivek Subbiah, MD @VivekSubbiah]

🎯🥁New druggable alteration in lung cancer 👉Another win for #PrecisionMedicine👉Discovery of a novel fusion driver, rapid bench to bedside translation
👉CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer 🫁🧬 #LCSM @Nature @OncoAlert https://t.co/X8vt9QW8Ad

[Madhu Eluri, MD @MadhuEluri]

Loving the @ASCO eLearning podcast and recommend other #hemonc trainees to check it out - current topics with experts, perfect for the 🚶🏻‍♀️or 🚙 to work!

[Eric K. Singhi, MD @lungoncdoc]

🚨 FDA Approves Adjuvant Atezolizumab for Stage II-IIIA NSCLC after resection & platinum-based chemo w/ PD-L1 ≥ 1% given positive DFS benefit seen in phase 3 IMpower010
https://t.co/0iG03xJREp @OncoAlert @onclive #lcsm

[Eric K. Singhi, MD @lungoncdoc]

🔥Excellent case conference series by PL-1 @AnoutiBilal re: management of patients w/ EGFR exon 20 insertion+ NSCLC. Nice review of recent FDA approvals & discussion of complex considerations like SOC 1L therapy & CNS disease. Thanks to @YYElamin for being our expert discussant!

[Vivek Subbiah, MD @VivekSubbiah]

⭐️How many times do cancer researchers get featured in the weekend edition of THE WALL STREET JOURNAL @WSJ! An honor to be among the recipients of 2021 Andrew Sabin Award @MDAndersonNews. This acknowledges the commitment of our research teams, patients, & families to #endcancer

[Sinchita Roy MD PhD @Sinchita_Roy]

From @MDAndersonNews @JMPRobichaux et al. Outstanding work on #lungcancer and structural classification for drug response in patients with EGFR mutations

[UT MD Anderson @UTMDAnderson]

Being presented by Dr. Andy Hahn at #ESMO21, a recent study suggests cytoreductive nephrectomy should be considered in patients with certain types of renal cell carcinoma treated with immune checkpoint inhibitors: https://t.co/PEMVPxRHzr. #EndCancer